Episode Details

Back to Episodes
Aardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome early next year, and is also working on weight loss

Aardvark Therapeutics' approach to obesity is to inhibit hunger (vs appetite). It has a key pivotal trial scheduled to read in Prader-Willi syndrome early next year, and is also working on weight loss

Published 10 months ago
Description

Founder and CEO Tien Lee describes how Aardvark's approach focuses on the gut-brain axis.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us